PubRank

A von Eckardstein

Author PubWeight™ 71.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 2.70
2 Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001 1.75
3 A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A 1991 1.69
4 C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000 1.63
5 Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996 1.55
6 D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999 1.48
7 Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001 1.43
8 Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J Biol Chem 2001 1.43
9 Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem 2001 1.29
10 The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998 1.26
11 Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 2011 1.25
12 Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999 1.19
13 Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J Mol Med (Berl) 2000 1.18
14 Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem 1998 1.17
15 A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest 1991 1.16
16 A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A 1994 1.13
17 Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J 1999 1.10
18 The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 2002 1.10
19 Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999 1.05
20 The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 2001 1.04
21 Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995 1.03
22 Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest 1998 1.00
23 Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest 1993 0.99
24 Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb 1993 0.98
25 Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 1999 0.97
26 Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat Genet 1998 0.93
27 Determinants of short-period heart rate variability in the general population. Cardiology 2001 0.92
28 High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. Thromb Haemost 2001 0.91
29 Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest 1995 0.90
30 Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 2000 0.90
31 High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 1993 0.89
32 [Obesity and cardiovascular risk]. Herz 2001 0.89
33 An ecological study of determinants of coronary heart disease rates: a comparison of Czech, Bavarian and Israeli men. Int J Epidemiol 1999 0.89
34 Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol (Oxf) 2000 0.87
35 Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. Clin Chem 1997 0.87
36 Before and after hip fracture, vitamin D deficiency may not be treated sufficiently. Osteoporos Int 2013 0.87
37 Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci U S A 1998 0.87
38 Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1999 0.85
39 Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III(Asp45-->Asn), in a Turkish patient. J Lipid Res 1994 0.85
40 Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Coron Artery Dis 2001 0.85
41 Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry 2000 0.85
42 The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-IMilano. Atherosclerosis 1997 0.85
43 Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 1999 0.84
44 Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 2001 0.84
45 Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux. J Mol Med (Berl) 1999 0.83
46 Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost 2000 0.81
47 Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group. Arterioscler Thromb Vasc Biol 1995 0.81
48 Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. Handb Exp Pharmacol 2005 0.81
49 Evaluation of lipoprotein(a) and genetic prothrombotic risk factors in patients with recurrent foetal loss. Thromb Haemost 2000 0.80
50 Structural and functional properties of reconstituted high density lipoprotein discs prepared with six apolipoprotein A-I variants. J Lipid Res 1991 0.80
51 Diagnosis and management of new cardiovascular risk factors. Eur Heart J 1998 0.80
52 Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997 0.80
53 Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin. Int J Obes Relat Metab Disord 2000 0.80
54 Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers. J Lipid Res 1999 0.80
55 Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I. J Lipid Res 1997 0.80
56 Gender-Related Differences in Patients Presenting with Suspected Acute Coronary Syndromes: Clinical Presentation, Biomarkers and Diagnosis. Cardiology 2015 0.79
57 Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol. Circulation 1999 0.79
58 Generation of pre-beta 1-HDL and conversion into alpha-HDL. Evidence for disturbed HDL conversion in Tangier disease. Arterioscler Thromb Vasc Biol 1995 0.79
59 Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal, apolipoprotein A-I-, and apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1997 0.79
60 The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group. Eur J Haematol 2001 0.79
61 Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1998 0.79
62 A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas. Arterioscler Thromb 1994 0.79
63 Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis 1998 0.78
64 Screening for naturally occurring apolipoprotein A-I variants: apo A-I(delta K107) is associated with low HDL-cholesterol levels in men but not in women. Hum Genet 1995 0.78
65 Structural and functional properties of natural and chemical variants of apolipoprotein A-I. Biochim Biophys Acta 1993 0.78
66 Macrophage function and stability of the atherosclerotic plaque: progress report of a European project. Nutr Metab Cardiovasc Dis 2002 0.78
67 Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. Eur J Clin Pharmacol 2004 0.78
68 Mannitol prevents methionine sulphoxidation mediated electrophoretic heterogeneity of apolipoprotein A-I. Biomed Chromatogr 1995 0.77
69 Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Arterioscler Thromb Vasc Biol 1999 0.77
70 Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. Exp Clin Endocrinol Diabetes 1999 0.77
71 A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma. J Lipid Res 1997 0.77
72 In vivo kinetics of human apolipoprotein A-I variants in rabbits. Eur J Clin Invest 1999 0.76
73 Basal growth hormone levels in women are positively correlated with high-density lipoprotein cholesterol and apolipoprotein A-I independently of insulin-like growth factor 1 or insulin. Metabolism 1998 0.76
74 Associations between homocysteine and coagulation factors--a cross-sectional study in two populations of central Europe. Thromb Res 2001 0.75
75 Effect of hypertriglyceridaemia on lipoprotein (a) serum concentrations. Eur J Clin Invest 1995 0.75
76 Diagnosis of iron deficiency in patients infected with human immunodeficiency virus. Haematologica 2000 0.75
77 Basal growth hormone levels are positively correlated with high-density lipoprotein cholesterol levels in women. Metabolism 1997 0.75
78 Compound heterozygosity for a known (D250N) and a novel (E410K) missense mutation in the C-terminal domain of lipoprotein lipase causes familial chylomicronemia. Hum Mutat 1996 0.75
79 [New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology]. Internist (Berl) 2014 0.75
80 Prevention of coronary heart disease in post-menopausal women. Nutr Metab Cardiovasc Dis 2000 0.75
81 European Lipoprotein Club: report of the 26th ELC Annual Conference, Tutzing, 8-11 September 2003. Atherosclerosis 2004 0.75
82 Correction: Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. PLoS One 2017 0.75
83 Electrophoretic screening for human apolipoprotein C-II variants: repeated identification of apolipoprotein C-II(K19T). J Mol Med (Berl) 1995 0.75
84 Polymorphic site study at codon 347 of apolipoprotein A-IV in a Japanese population. Biochim Biophys Acta 1993 0.75
85 Elevated low-density lipoprotein-cholesterol in women with polycystic ovary syndrome. Gynecol Endocrinol 1996 0.75
86 [Clinical and biochemical characteristics of a new case of Tangier disease in Spain]. Med Clin (Barc) 1998 0.75
87 Elecsys CEA, PSA and AFP. Clinical results of a multicentre evaluation. Wien Klin Wochenschr 1998 0.75
88 Genetically determined absence of HDL-cholesterol and coronary atherosclerosis. Lancet 1995 0.75
89 Cholesterol efflux from normal and Tangier disease fibroblasts into normal, high-density lipoprotein-deficient, and apolipoprotein E-deficient plasmas. Metabolism 2000 0.75